Compile Data Set for Download or QSAR
Report error Found 564 Enz. Inhib. hit(s) with all data for entry = 10313
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527092(US11186582, Example 375)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527091(US11186582, Example 374)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236226(CHEMBL4087412 | US11186582, Example 378 | US114198...)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527093(US11186582, Example 377)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527096(US11186582, Example 384)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527095(US11186582, Example 382)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527098(US11186582, Example 394)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527097(US11186582, Example 389)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527100(US11186582, Example 397)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527099(US11186582, Example 396)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527102(US11186582, Example 407)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527101(US11186582, Example 406)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527104(US11186582, Example 419)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527103(US11186582, Example 414)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527106(US11186582, Example 421)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527105(US11186582, Example 420)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236231(CHEMBL4087945 | US11186582, Example 349 | US114198...)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527075(US11186582, Example 348)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527078(US11186582, Example 352)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527077(US11186582, Example 350)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527080(US11186582, Example 355)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527079(US11186582, Example 353)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527082(US11186582, Example 358)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527081(US11186582, Example 357)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527084(US11186582, Example 363)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527083(US11186582, Example 362)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527086(US11186582, Example 366)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527085(US11186582, Example 365)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527088(US11186582, Example 368)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527087(US11186582, Example 367)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527090(US11186582, Example 372)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527089(US11186582, Example 370)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527124(US11186582, Example 493)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM50236241(CHEMBL4069050 | US11186582, Example 481)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527126(US11186582, Example 499)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527125(US11186582, Example 498)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527128(US11186582, Example 502)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527127(US11186582, Example 501)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527130(US11186582, Example 504)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527129(US11186582, Example 503)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527132(US11186582, Example 507)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527131(US11186582, Example 505)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527134(US11186582, Example 509)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527133(US11186582, Example 508)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527136(US11186582, Example 511)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527135(US11186582, Example 510)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527138(US11186582, Example 514)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527137(US11186582, Example 513)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527108(US11186582, Example 424)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM527107(US11186582, Example 423)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

Displayed 1 to 50 (of 564 total ) | Next | Last >>
Jump to: